Key result
Lung cancer and HF publications grow ~8% annually, reflecting rising interest in treatment-induced cardiotoxicity.
Why the study?
Studies on the two-way interaction between lung cancer and heart failure remain scarce, despite an increasing focus on treatment-induced cardiotoxicity.
Bibliometric analysis reveals a rapidly growing research focus on the intersection of lung cancer and heart failure, driven largely by the cardiotoxic effects of modern cancer therapies like immune checkpoint inhibitors.
May warrant HF surveillance during lung cancer therapy; extends bibliometric insights into cardio-oncology.
This innovative mapping research highlights an increasing focus on the link between LC and HF, particularly concerning treatment-induced cardiotoxicity. Nonetheless, studies on their two-way interaction are still scarce, pointing to a promising yet under-researched area. Combining oncology and cardiology could reveal new insights to tailor personalized care and enhance results. Our research provides a foundation for future interdisciplinary investigations in the developing field of cardio-oncology.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied lung cancer and heart failure (n=531). The publication output related to lung cancer and heart failure showed a significant annual growth rate of 7.92% from 2014 to 2024, reflecting increasing research interest in treatment-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: